Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
AI Summary
Eli Lilly is set to acquire psychedelics maker AtaiBeckley for $2.8 billion, gaining access to innovative experimental drugs based on psychedelics DMT and MDMA. This move reflects growing interest in novel treatment options within the pharmaceutical market.
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.